logo-loader
viewCatalyst Pharmaceuticals Inc

Catalyst Pharma shares crash on FDA letter news

Shares in Catalyst Pharmaceuticals crashed more than 40% after the firm, which is developing therapies for people with rare debilitating diseases, received a 'Refusal to File' letter from the US FDA.

sareum-test-tubes.png
The biotech firm plans to request a meeting with the FDA to discuss the matter and hopefully reach an understanding as to what will be required for the Firdapse NDA to be filed by FDA for review...

Shares  in Catalyst Pharmaceuticals (NASDAQ:CPRX) crashed more than 40% after the firm, which is developing therapies for people with rare debilitating diseases, received a 'Refusal to File' letter from the US FDA.

Shares lost 40.59% on Nasdaq to stand at US$1.10 each.

It's in regard to its new drug application for Firdapse (amifampridine phosphate) - an investigational drug candidate for treating rare autoimmune, neuromuscular disorders Lambert Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS).

The FDA says the application, which was submitted in December 2015, was not sufficiently complete, and requests additional information. 

The biotech firm plans to request a meeting with the FDA to discuss the matter and hopefully reach an understanding as to what will be required for the Firdapse NDA to be filed by FDA for review.

"We expect to work closely with the FDA over the coming weeks in an effort to resolve the open issues and to define a path forward for a successful resubmission of our application at the earliest point in time," said Patrick McEnany, chairman and chief executive.

"We remain focused on delivering on our promise to transform the way people living with LEMS and CMS are provided access to a safe and effective, FDA approved therapy.

"Additionally, our Expanded Access Program continues to enroll new patients and provide Firdapse at no cost to patients who meet the enrollment criteria."

Catalyst has previously received orphan drug status for Firdapse to treat LEMS and CMS, and Breakthrough Therapy Designation for Firdapse to treat LEMS.

Quick facts: Catalyst Pharmaceuticals Inc

Price: 3.47 USD

NASDAQ:CPRX
Market: NASDAQ
Market Cap: $359.02 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Auryn Resources spins our Peruvian assets creating a new company called Fury...

Auryn Resources (TSE: AUG- NYSEAMERICAN: AUG) Executive Chairman Ivan Bebek and new company Fury Gold Mines CEO Mike Timmins joined Steve Darling from Proactive Vancouver with news Auryn is creating a new gold-focused exploration and development company called Fury Gold Mines. Bebek discusses...

20 hours, 3 minutes ago

2 min read